{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:42:59Z","timestamp":1781206979872,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31871361"],"award-info":[{"award-number":["31871361"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31871361"],"award-info":[{"award-number":["31871361"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The development of drug resistance is a major cause of cancer therapy failures. To inhibit drug resistance, multiple drugs are often treated together as a combinatorial therapy. In particular, synergistic drug combinations, which kill cancer cells at a lower concentration, guarantee a better prognosis and fewer side effects in cancer patients. Many studies have sought out synergistic combinations by small-scale function-based targeted growth assays or large-scale nontargeted growth assays, but their discoveries are always challenging due to technical problems such as a large number of possible test combinations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To address this issue, we carried out a medium-scale optical drug synergy screening in a non-small cell lung cancer cell line and further investigated individual drug interactions in combination drug responses by high-content image analysis. Optical high-content analysis of cellular responses has recently attracted much interest in the field of drug discovery, functional genomics, and toxicology. Here, we adopted a similar approach to study combinatorial drug responses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>By examining all possible combinations of 12 drug compounds in 6 different drug classes, such as mTOR inhibitors, HDAC inhibitors, HSP90 inhibitors, MT inhibitors, DNA inhibitors, and proteasome inhibitors, we successfully identified synergism between INK128, an mTOR inhibitor, and HDAC inhibitors, which has also been reported elsewhere. Our high-content analysis further showed that HDAC inhibitors, HSP90 inhibitors, and proteasome inhibitors played a dominant role in combinatorial drug responses when they were mixed with MT inhibitors, DNA inhibitors, or mTOR inhibitors, suggesting that recessive drugs could be less prioritized as components of multidrug cocktails.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, our optical drug screening platform efficiently identified synergistic drug combinations in a non-small cell lung cancer cell line, and our high-content analysis further revealed how individual drugs in the drug mix interact with each other to generate combinatorial drug response.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12057-4","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T22:01:26Z","timestamp":1710280886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line"],"prefix":"10.1186","volume":"24","author":[{"given":"Sijiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliano","family":"Oliveira-Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungseog","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"issue":"7","key":"12057_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41576-019-0114-6","volume":"20","author":"S Turajlic","year":"2019","unstructured":"Turajlic S, et al. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019;20(7):404\u201316.","journal-title":"Nat Rev Genet"},{"issue":"2","key":"12057_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"12057_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nbt.2284","volume":"30","author":"B Al-Lazikani","year":"2012","unstructured":"Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679\u201392.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"12057_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","volume":"14","author":"JS Lopez","year":"2017","unstructured":"Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 2017;14(1):57\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"12057_CR5","doi-asserted-by":"publisher","first-page":"100110","DOI":"10.1016\/j.crphar.2022.100110","volume":"3","author":"D Duarte","year":"2022","unstructured":"Duarte D, Vale N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov. 2022;3:100110.","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"12057_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.coph.2018.07.008","volume":"42","author":"T Pemovska","year":"2018","unstructured":"Pemovska T, Bigenzahn JW, Superti-Furga G. Recent advances in combinatorial drug screening and synergy scoring. Curr Opin Pharmacol. 2018;42:102\u201310.","journal-title":"Curr Opin Pharmacol"},{"key":"12057_CR7","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1038\/srep05193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav B, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep. 2014;4:5193.","journal-title":"Sci Rep"},{"issue":"7899","key":"12057_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","volume":"603","author":"P Jaaks","year":"2022","unstructured":"Jaaks P, et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature. 2022;603(7899):166\u201373.","journal-title":"Nature"},{"issue":"11","key":"12057_CR9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/nbt.2391","volume":"30","author":"X Tan","year":"2012","unstructured":"Tan X, et al. Systematic identification of synergistic drug pairs targeting HIV. Nat Biotechnol. 2012;30(11):1125\u201330.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"12057_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41597-019-0255-7","volume":"6","author":"\u00c5 Flobak","year":"2019","unstructured":"Flobak \u00c5, et al. A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines. Scientific Data. 2019;6(1):237.","journal-title":"Scientific Data"},{"key":"12057_CR11","doi-asserted-by":"publisher","first-page":"14508","DOI":"10.1038\/srep14508","volume":"5","author":"A Weiss","year":"2015","unstructured":"Weiss A, et al. A streamlined search technology for identification of synergistic drug combinations. Sci Rep. 2015;5:14508.","journal-title":"Sci Rep"},{"issue":"3","key":"12057_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1158\/1535-7163.MCT-08-0937","volume":"8","author":"RG Zinner","year":"2009","unstructured":"Zinner RG, et al. Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol Cancer Ther. 2009;8(3):521\u201332.","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 1","key":"12057_CR13","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1186\/1471-2105-12-S1-S18","volume":"12 Suppl 1","author":"BJ Yoon","year":"2011","unstructured":"Yoon BJ. Enhanced stochastic optimization algorithm for finding effective multi-target therapeutics. BMC Bioinformatics. 2011;12 Suppl 1(Suppl 1):S18.","journal-title":"BMC Bioinformatics"},{"issue":"12","key":"12057_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.15252\/msb.20156400","volume":"11","author":"M Breinig","year":"2015","unstructured":"Breinig M, et al. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells. Mol Syst Biol. 2015;11(12):846.","journal-title":"Mol Syst Biol"},{"issue":"1","key":"12057_CR15","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41467-017-01383-w","volume":"8","author":"M Niepel","year":"2017","unstructured":"Niepel M, et al. Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nat Commun. 2017;8(1):1186.","journal-title":"Nat Commun"},{"issue":"1","key":"12057_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1083\/jcb.201610026","volume":"216","author":"BT Grys","year":"2017","unstructured":"Grys BT, et al. Machine learning and computer vision approaches for phenotypic profiling. J Cell Biol. 2017;216(1):65\u201371.","journal-title":"J Cell Biol"},{"issue":"9","key":"12057_CR17","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nmeth.4397","volume":"14","author":"JC Caicedo","year":"2017","unstructured":"Caicedo JC, et al. Data-analysis strategies for image-based cell profiling. Nat Methods. 2017;14(9):849\u201363.","journal-title":"Nat Methods"},{"issue":"9","key":"12057_CR18","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/nprot.2016.105","volume":"11","author":"MA Bray","year":"2016","unstructured":"Bray MA, et al. Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat Protoc. 2016;11(9):1757\u201374.","journal-title":"Nat Protoc"},{"issue":"6","key":"12057_CR19","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.cell.2015.11.007","volume":"163","author":"M Boutros","year":"2015","unstructured":"Boutros M, Heigwer F, Laufer C. Microscopy-Based High-Content Screening. Cell. 2015;163(6):1314\u201325.","journal-title":"Cell"},{"issue":"1","key":"12057_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt.3419","volume":"34","author":"J Kang","year":"2016","unstructured":"Kang J, et al. Improving drug discovery with high-content phenotypic screens by systematic selection of reporter cell lines. Nat Biotechnol. 2016;34(1):70\u20137.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"12057_CR21","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41467-020-14978-7","volume":"11","author":"L Stojic","year":"2020","unstructured":"Stojic L, et al. A high-content RNAi screen reveals multiple roles for long noncoding RNAs in cell division. Nat Commun. 2020;11(1):1851.","journal-title":"Nat Commun"},{"issue":"12","key":"12057_CR22","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1007\/s00204-019-02593-5","volume":"93","author":"S Li","year":"2019","unstructured":"Li S, Xia M. Review of high-content screening applications in toxicology. Arch Toxicol. 2019;93(12):3387\u201396.","journal-title":"Arch Toxicol"},{"key":"12057_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.copbio.2016.04.003","volume":"39","author":"JC Caicedo","year":"2016","unstructured":"Caicedo JC, Singh S, Carpenter AE. Applications in image-based profiling of perturbations. Curr Opin Biotechnol. 2016;39:134\u201342.","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"12057_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nchembio.2007.53","volume":"4","author":"DW Young","year":"2008","unstructured":"Young DW, et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol. 2008;4(1):59\u201368.","journal-title":"Nat Chem Biol"},{"issue":"12","key":"12057_CR25","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.chembiol.2012.10.014","volume":"19","author":"Y Futamura","year":"2012","unstructured":"Futamura Y, et al. Morphobase, an encyclopedic cell morphology database, and its use for drug target identification. Chem Biol. 2012;19(12):1620\u201330.","journal-title":"Chem Biol"},{"issue":"11","key":"12057_CR26","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1039\/c3mb70245f","volume":"9","author":"MH Woehrmann","year":"2013","unstructured":"Woehrmann MH, et al. Large-scale cytological profiling for functional analysis of bioactive compounds. Mol Biosyst. 2013;9(11):2604\u201317.","journal-title":"Mol Biosyst"},{"issue":"2","key":"12057_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.chembiol.2012.12.007","volume":"20","author":"CJ Schulze","year":"2013","unstructured":"Schulze CJ, et al. \u201cFunction-first\u201d lead discovery: mode of action profiling of natural product libraries using image-based screening. Chem Biol. 2013;20(2):285\u201395.","journal-title":"Chem Biol"},{"issue":"9","key":"12057_CR28","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1021\/acs.jnatprod.5b00455","volume":"78","author":"JL Ochoa","year":"2015","unstructured":"Ochoa JL, et al. Phenotype-guided natural products discovery using cytological profiling. J Nat Prod. 2015;78(9):2242\u20138.","journal-title":"J Nat Prod"},{"issue":"6","key":"12057_CR29","doi-asserted-by":"publisher","first-page":"ar49","DOI":"10.1091\/mbc.E21-11-0538","volume":"33","author":"JC Caicedo","year":"2022","unstructured":"Caicedo JC, et al. Cell painting predicts impact of lung cancer variants. Mol Biol Cell. 2022;33(6):ar49.","journal-title":"Mol Biol Cell"},{"key":"12057_CR30","doi-asserted-by":"crossref","unstructured":"Rohban MH. et al. Systematic morphological profiling of human gene and allele function via cell painting. Elife. 2017;6:e24060.","DOI":"10.7554\/eLife.24060"},{"key":"12057_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fonc.2018.00267","volume":"8","author":"V Sosa Iglesias","year":"2018","unstructured":"Sosa Iglesias V, et al. Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting? Front Oncol. 2018;8:267.","journal-title":"Front Oncol"},{"issue":"1\u20132","key":"12057_CR32","first-page":"96","volume":"85","author":"VML de Sousa","year":"2018","unstructured":"de Sousa VML, Carvalho L. Heterogeneity in lung cancer. Pathobiology. 2018;85(1\u20132):96\u2013107.","journal-title":"Pathobiology"},{"issue":"1","key":"12057_CR33","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12935-022-02807-4","volume":"22","author":"T Mao","year":"2022","unstructured":"Mao T, et al. HDACs\/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. Cancer Cell Int. 2022;22(1):380.","journal-title":"Cancer Cell Int"},{"issue":"9","key":"12057_CR34","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-17-0171","volume":"16","author":"JK Simmons","year":"2017","unstructured":"Simmons JK, et al. Cooperative targets of combined mTOR\/HDAC inhibition promote MYC degradation. Mol Cancer Ther. 2017;16(9):2008\u201321.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"12057_CR35","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.18632\/oncotarget.2992","volume":"6","author":"BR Beagle","year":"2015","unstructured":"Beagle BR, et al. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget. 2015;6(4):2088\u2013100.","journal-title":"Oncotarget"},{"issue":"6","key":"12057_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner M, et al. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods. 2016;13(6):521\u20137.","journal-title":"Nat Methods"},{"issue":"5","key":"12057_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cell.2010.02.011","volume":"140","author":"N Geva-Zatorsky","year":"2010","unstructured":"Geva-Zatorsky N, et al. Protein dynamics in drug combinations: a linear superposition of individual-drug responses. Cell. 2010;140(5):643\u201351.","journal-title":"Cell"},{"issue":"2","key":"12057_CR38","doi-asserted-by":"publisher","first-page":"E170","DOI":"10.1073\/pnas.1210419110","volume":"110","author":"JR Pritchard","year":"2013","unstructured":"Pritchard JR, et al. Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A. 2013;110(2):E170\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7\u201312","key":"12057_CR39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/14786440109462720","volume":"2","author":"K Pearson","year":"1901","unstructured":"Pearson K. On lines and planes of closest fit to systems of points in space. Phil Mag. 1901;2(7\u201312):559\u201372.","journal-title":"Phil Mag"},{"issue":"5","key":"12057_CR40","first-page":"116","volume":"14","author":"J Stevens","year":"1984","unstructured":"Stevens J. Applied multivariate statistical-analysis - Johnson, R, Wichern. D Interfaces. 1984;14(5):116\u20138.","journal-title":"D Interfaces"},{"key":"12057_CR41","first-page":"1027","volume":"8","author":"M Sugiyama","year":"2007","unstructured":"Sugiyama M. Dimensionality reduction of multimodal labeled data by local fisher discriminant analysis. J Mach Learn Res. 2007;8:1027\u201361.","journal-title":"J Mach Learn Res"},{"issue":"7","key":"12057_CR42","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell. 2017;171(7):1678\u20131691.e13.","journal-title":"Cell"},{"issue":"13","key":"12057_CR43","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.18632\/oncotarget.2077","volume":"5","author":"SH Millson","year":"2014","unstructured":"Millson SH, Piper PW. Insights from yeast into whether the inhibition of heat shock transcription factor (Hsf1) by rapamycin can prevent the Hsf1 activation that results from treatment with an Hsp90 inhibitor. Oncotarget. 2014;5(13):5054\u201364.","journal-title":"Oncotarget"},{"issue":"9","key":"12057_CR44","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1158\/1535-7163.MCT-16-0848","volume":"16","author":"L Giulino-Roth","year":"2017","unstructured":"Giulino-Roth L, et al. Inhibition of Hsp90 Suppresses PI3K\/AKT\/mTOR signaling and has antitumor activity in Burkitt lymphoma. Mol Cancer Ther. 2017;16(9):1779\u201390.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"12057_CR45","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3349\/ymj.2020.61.7.587","volume":"61","author":"HJ Kim","year":"2020","unstructured":"Kim HJ, et al. Synergistic antitumor effects of combined treatment with HSP90 inhibitor and PI3K\/mTOR dual inhibitor in Cisplatin-resistant human bladder cancer cells. Yonsei Med J. 2020;61(7):587\u201396.","journal-title":"Yonsei Med J"},{"key":"12057_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27\u201355.","journal-title":"Adv Enzyme Regul"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12057-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12057-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12057-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T13:06:24Z","timestamp":1730984784000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12057-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12057"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12057-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"7 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"335"}}